Transforming medical innovations currently at the prototype stage into reality to better combat the threat of Emerging Infectious Diseases & AMR

IDCluster’s purpose is to accelerate the market launch of innovative products for patients or to accelerate the use of solutions for public authorities in the two areas of MIE and AMR, by transforming accelerated R&D projects from their prototype stage into reality.

Facilitate acceleration

Thanks to collaboration with French and European public authorities, based on proposals formalized by IDCluster on issues such as:

Facilitating administrative and regulatory procedures for the commercialization of innovations.
For example, by gathering and compiling the views of industry players, particularly those of innovation leaders, founders, and IDCluster partners, to identify obstacles and/or pitfalls that hinder, complicate, and/or slow down the development of the healthcare products in question.

The economic model for financing innovations in the two areas of EID & AMR, given the risk of market failure (see the strategic dimension Taking into account the risk of market failure in the previous document).

Through skills development

This involves identifying the need for new skills and jobs, attracting talent, and promoting the recruitment and training of employees that companies will need in the two areas of EID and AMR.

Through the integration of user and patient relationships from the moment projects are accelerated by IDCluster to ensure their relevance and impact.

The aim is to promote an innovation approach focused on their real needs, experience, and expertise.
This recognition of users’ experiential knowledge complements scientific and medical approaches, enriching research, prevention, and therapeutic support strategies.

IDCluster activities

ID360 Platform

Stimulate innovation

Accelerate innovation

Facilitate acceleration